Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][3] - The company will participate in the 2025 BIO CEO & Investor Conference, highlighting its commitment to addressing mental health through innovative targets and endpoints [1][2] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries, indicating a strong intellectual property position [3]
Reviva to Participate in the 2025 BIO CEO & Investor Conference